First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy

被引：0
|
作者：
Kozak, K. [1 ]
Teterycz, P. [1 ]
Galus, L. [2 ]
Mackiewicz, J. [2 ]
Brandys, P. [3 ]
Cybulska-Stopa, B. [4 ]
Kempa-Kaminska, N. [4 ]
Zietek, M. [5 ]
Zubrowska, J. [6 ]
Dziura, R. [6 ]
Sobczuk, P. [1 ]
Czarnecka, A. M. [7 ,8 ,9 ]
Rutkowski, P. [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[2] Poznan Univ Med Sci, Inst Oncol, Dept Med & Expt Oncol, Poznan, Poland
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Krakow Branch, Krakow, Poland
[4] Lower Silesian Ctr Oncol Hematol & Pulmonol, Dept Clin Oncol, Wroclaw, Poland
[5] Wroclaw Comprehens Canc Ctr, Dept Surg Oncol, Wroclaw, Poland
[6] Holy Cross Canc Ctr, Dept Clin Oncol, Kielce, Poland
[7] Polish Acad Sci, Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[8] Polish Acad Sci, Maria Sklodowska Curie Natl Res Inst Oncol, Dept Expt Pharmacol, Warsaw, Poland
[9] Polish Acad Sci, Med Res Ctr, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105P
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [1] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Metastatic Melanoma Nivolumab plus Ipilimumab is the better First-line Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 448 - 449
  • [3] Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
    Mehmi, Inderjit
    Hamid, Omid
    Hodi, F. Stephen
    Vassalo, Melinda
    Malatyali, Saundra
    Krishnarajapet, Swathi
    O'Donnell, Nan
    Castrence, Angeli
    Lim, Eunice
    Gormley, Jill
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [5] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [6] Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
    Mason, Robert
    Dearden, Helen C.
    Nguyen, Bella
    Soon, Jennifer A.
    Smith, Jessica Louise
    Randhawa, Manreet
    Mant, Andrew
    Warburton, Lydai
    Lo, Serigne
    Meniawy, Tarek
    Guminski, Alexander
    Parente, Phillip
    Ali, Sayed
    Haydon, Andrew
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Atkinson, Victoria G.
    Menzies, Alexander M.
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 358 - 365
  • [7] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
  • [8] EFFICACY OF NIVOLUMAB PLUS IPILIMUMAB IN PRIMARY TUMOR AS FIRST-LINE THERAPY IN THE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
    Kikuchi, Hiroshi
    Osawa, Takahiro
    Matsumoto, Ryuji
    Abe, Takashige
    Maruyama, Satoru
    Harabayashi, Toru
    Miyata, Haruka
    Kashiwagi, Akira
    Sazawa, Ataru
    Fukui, Riyo
    Morita, Ken
    Takeuchi, Ichiro
    Yamashita, Noboru
    Minami, Keita
    Mochizuki, Tango
    Shinohara, Nobuo
    JOURNAL OF UROLOGY, 2021, 206 : E259 - E259
  • [9] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [10] Ipilimumab In Previously Treated Patients with Advanced Melanoma
    Sanford, Mark
    BIODRUGS, 2012, 26 (03) : 185 - 193
12345